Description
TAS-120 is an investigational medication currently being studied in clinical trials. It is being evaluated as a potential treatment for various types of cancer, including colorectal cancer. The trials are in early phases (Phase 1), focusing on determining the safe dosage and how patients tolerate the drug. TAS-120 is being tested alone and in combination with other cancer treatments, such as chemotherapy agents (like 5-Fluorouracil, Gemcitabine, Nab-Paclitaxel) and targeted therapies (like Bevacizumab, Ramucirumab). Some trials are specifically looking at patients whose tumors have certain genetic changes (mutations) like EGFR, KRAS, MET, NRAS, VEGF, or specific levels of PD-L1 expression. The goal of these early trials is to gather initial safety and efficacy data.
Mechanism of Action
The specific way TAS-120 works (its mechanism of action) is still under investigation in clinical trials. It is being studied to see how it affects cancer cells and tumor growth. The trials will help researchers understand its potential targets and effects within the body.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Category | Other Medications |
 EMA Status | Experimental |
 Spain Access | Not available |
| Clinical Trials | 1 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.